glp-1 food trends news Use and Its Impact on Choices and Retail Behavior Specialty Food News | Specialty

last year, are taking note

This distinct clustering indicates a profound change in the plasma proteome following semaglutide treatment

HM15275 and HM17321, both scheduled for presentation at ADA 2025, represent next-generation pipelines following the innovation of efpeglenatide, which is targeted for commercialization in the second half of 2026

Outcomes suggest semaglutide produced poorer outcomes, with a significantly elevated incidence of all-cause mortality (Risk Ratio [RR]: 1.56), AMI (RR: 1.21), ischemic stroke (RR: 1.64, p=0.024) and readmission (RR: 1.15) compared to tirzepatide

Clinical data show small differences in absorption between injection sites, but these differences are not considered clinically meaningful for most people

Absolutely, Alexander said